# Neoadjuvant LDRT Combined With Durvalumab in Potentially Resectable Stage III NSCLC

> **NCT05157542** · PHASE1 · UNKNOWN · sponsor: **Juan LI, MD** · enrollment: 9 (estimated)

## Conditions studied

- Stage III Non-small Cell Lung Cancer

## Interventions

- **DRUG:** Durvalumab
- **DRUG:** nanoparticle albumin bound paclitaxel
- **RADIATION:** low dose radiation therapy

## Key facts

- **NCT ID:** NCT05157542
- **Lead sponsor:** Juan LI, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-06-10
- **Primary completion:** 2023-06-10
- **Final completion:** 2023-06-10
- **Target enrollment:** 9 (ESTIMATED)
- **Last updated:** 2021-12-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05157542

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05157542, "Neoadjuvant LDRT Combined With Durvalumab in Potentially Resectable Stage III NSCLC". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05157542. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*